National Meeting of the American College of Rheumatology. November 8-12, 1998, San Diego, California.
Badii
M
M
Arthritis Society, Vancouver BC. mbadii@bc.arthritis.ca
D000814:Aniline Compounds / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003437:Crotonates; D000068800:Etanercept; D006801:Humans; D006885:Hydroxybutyrates / Q000494:pharmacology; D007074:Immunoglobulin G / Q000627:therapeutic use; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D000069285:Infliximab; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D009570:Nitriles; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014052:Toluidines; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States
D000814:Aniline Compounds; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003437:Crotonates; D006885:Hydroxybutyrates; D007074:Immunoglobulin G; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D007555:Isoxazoles; D009570:Nitriles; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014052:Toluidines; D014409:Tumor Necrosis Factor-alpha; C527525:teriflunomide; C099374:Ro 45-2081; D000069285:Infliximab; D000077339:Leflunomide; D000068800:Etanercept